Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2005, Vol. 10 ›› Issue (6): 717-720.

Previous Articles    

Influence of rosiglitazone and metformin on blood pressure in treatment of patients with type 2 diabetes mellitus

LI Hong-hui, LIU En-bo, XIE Qun, DING Su-jie, HE Tao1, LI Jia-fu1   

  1. Department of Endocrinology, Luohu People’s Hospital, Shenzhen 518001, Guangdong, China;1Department of Cardiology, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, Guangxi, China
  • Received:2005-01-19 Revised:2005-04-21 Online:2005-06-26 Published:2020-11-12

Abstract: AIM: To investigate the influence of insulinsensitizer (Rosiglitazone) and metformin on blood pressure in treatment of patients with type 2 diabetes mellitus. METHODS: 58 patients with type 2 diabetes mellitus were randomly assigned to two groups.Patients orally received rosiglitazone 4-8 mg, qd, or metformin 250-500 mg, tid, for 12 weeks. The patients did not take any hypotensive drug during the investigation. BP, blood glucose and insulin were measured before and after treatment. The insulin resistance index and insulin sensitive index were calculated. RESULTS: SBP and DBP decreased after treatment by rosiglitazone and metformin (P <0.05). The decrease of blood pressure in rosiglitazone group were more than that in metformin group. FBG, PBG and FINS and PINS decreased after treatment (P < 0.05). ISI increased and IR decreased in the two groups (P <0.05). The extents of ISI and IR in rosiglitazone group were higher than that in metformin group. CONCLUSION: Rosiglitazone and metformin can effectively decrease IR and blood pressure, and the effect of rosiglitazone is better than that of metformin.

Key words: rosiglitazone, metformin, diabetes mellitus, blood pressure, insulinresistance

CLC Number: